No evidence for adjuvant chemotherapy in high-risk disease

被引：1
作者：
Albers, Peter [1 ]
机构：
[1] Univ Hosp, Dept Urol, D-40225 Dusseldorf, Germany
来源：
NATURE REVIEWS UROLOGY | 2015年 / 12卷 / 11期
关键词：
PROSTATE-CANCER; ANDROGEN SUPPRESSION; TRIAL; RADIOTHERAPY; RADIATION; THERAPY; EORTC;
D O I：
10.1038/nrurol.2015.219
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The RTOG trial investigated the survival benefit of chemotherapy combined with androgen deprivation therapy (ADT) in patients with high-risk nonmetastatic prostate cancer after radiotherapy. However, the 10-year overall survival data showed no difference between treatments; thus, chemotherapy is unlikely to improve the overall survival in patients with nonmetastatic prostate cancer.
引用
收藏
页码：602 / 603
页数：2
相关论文
共 9 条
  • [1] Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
    Albertsen, PC
    Hanley, JA
    Gleason, DF
    Barry, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 975 - 980
  • [2] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Bolla, M
    Collette, L
    Blank, L
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Mattelaer, J
    Torecilla, JL
    Pfeffer, JR
    Cutajar, CL
    Zurlo, A
    Pierart, M
    [J]. LANCET, 2002, 360 (9327) : 103 - 108
  • [3] Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
    Bolla, Michel
    van Poppel, Hein
    Tombal, Bertrand
    Vekemans, Kris
    Da Pozzo, Luigi
    de Reijke, Theo M.
    Verbaeys, Antony
    Bosset, Jean-Francois
    van Velthoven, Roland
    Colombel, Marc
    van de Beek, Cees
    Verhagen, Paul
    van den Bergh, Alphonsus
    Sternberg, Cora
    Gasser, Thomas
    van Tienhoven, Geertjan
    Scalliet, Pierre
    Haustermans, Karin
    Collette, Laurence
    [J]. LANCET, 2012, 380 (9858) : 2018 - 2027
  • [4] Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era
    D'Amico, AV
    Moul, J
    Carroll, PR
    Sun, L
    Lubeck, D
    Chen, MH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2163 - 2172
  • [5] Androgen suppression plus radiation versus radiation alone for patients with stage D1/Pathologic node-positive adenocarcinoma of the prostate:: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31
    Lawton, CA
    Winter, K
    Grignon, D
    Pilepich, MV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 800 - 807
  • [6] Rosenthal S. A., INT J RAD ONCOL BIOL
  • [7] PHASE III MULTI-INSTITUTIONAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND ORAL ETOPOSIDE COMBINED WITH LONG-TERM ANDROGEN SUPPRESSION THERAPY AND RADIOTHERAPY VERSUS LONG-TERM ANDROGEN SUPPRESSION PLUS RADIOTHERAPY ALONE FOR HIGH-RISK PROSTATE CANCER: PRELIMINARY TOXICITY ANALYSIS OF RTOG 99-02
    Rosenthal, Seth A.
    Bae, Kyoungwha
    Pienta, Kenneth J.
    Sobczak, Mark L.
    Asbell, Sucha O.
    Rajan, Raghu
    Kerlin, Kevin J.
    Michalski, Jeff M.
    Sandler, Howard M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03): : 672 - 678
  • [8] Sandler HM, 2015, J CLIN ONCOL, V33
  • [9] IS THERE EVIDENCE THAT CHEMOTHERAPY IS OF BENEFIT TO PATIENTS WITH CARCINOMA OF THE PROSTATE
    TANNOCK, IF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (07) : 1013 - 1021
1